MelliCell develops drug therapies that shrink fat cells in order to treat diabetes and other metabolic diseases like obesity. The company focuses on understanding and treating the root cause of diabetes at the cellular level.

MelliCell

Modular Medical focuses on providing tools to help healthcare providers manage diabetes care more effectively. The company's product, MODD1, is designed to simplify diabetes management.

Modular Medical

MelliCell, Inc. | 570 followers on LinkedIn. Where diabetes meets the cure | MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults.

Founder, Chief Executive Officer at MelliCell, Inc.

Ben Pope

Director of Medicinal Chemistry at MelliCell, Inc.

Prakash Jagtap

Co-Founder, MelliCell, Inc.

Prince Nnah

Business Analytics, Data Analysis, Healthcare, Research | Project Manager, SCRUM

Sunday (Sunny) Oworah, MBA, Data Analyst

MelliCell, Inc.

Today, we honor the courage, dedication, and sacrifice of our veterans. Their commitment to service inspires us to push forward in our mission to improve health and well-being. Thank you to all veterans for your bravery and the sacrifices you’ve made for our freedom. #VeteransDay #ThankYouVeterans # #HonorOurHeroes

Exciting News! 🎉 We are thrilled to announce that MelliCell, Inc. has been awarded a NIH/NIDDK SEED grant in partnership with Mass General Brigham ! This achievement reflects the collective efforts of our incredible team, and we'd like to extend special recognition to: Ben Pope – CEO, Mellicell Madhumita Basu – Principal Scientist, Target Discovery, Mellicell Luminita Pojoga – Associate Director, HMCI Lab, Mass General Brigham Thank you to everyone involved—your hard work and dedication made this milestone possible! With our M3 platform, we are unlocking the potential of fat cells to drive new therapies for diabetes, obesity and other metabolic diseases. Learn more: https://lnkd.in/e7b7yzzw #Fatcell #metabolicdiseasetherapy #NIH #NIDDK #MGH #Obesity #Diabetes

Check out this insightful interview with Dr. Prince Nnah, by Propel Labs! 🎥 In the interview, Prince discusses his vision for healthcare innovation and the groundbreaking work Team Mellicell is doing to tackle obesity, diabetes, and other metabolic diseases using our proprietary M3 technology. Watch the full interview here: https://lnkd.in/drdE3pqZ #HealthcareInnovation #Biotech #fatcells #Obesity #Diabetes #Metabolicdiseases #MelliCell

🎆 Happy Independence Day! 🎆 Today, we reflect on the 4th of July, celebrating freedom, courage, and unity. We honor the sacrifices of those who fought for our independence and the enduring spirit of innovation that shapes America. At Mellicell, we are inspired by these values as we strive to combat diabesity and improve lives. We are proud to be part of a nation where dreams are possible and innovation thrives. Wishing you and your loved ones a joyous and reflective 4th of July! 🇺🇸 #IndependenceDay #4thOfJuly #HealthcareInnovation #DiabesityAwareness #Obesity #Diabetes #Biotech

Dr. Fatima Coddy Stanford raises crucial safety concerns about counterfeit and compounded GLP-1 agents for obesity in her recent interview with WCVB-TV Channel 5 in Boston. These untested and unvalidated drugs pose serious health risks. It's essential to prioritize safety and use only FDA-approved treatments. Thank you, Jenny Barron, for your investigative work on this critical issue. #Obesity #GLP1 #Safety #Health https://lnkd.in/eSJYy_WN

Honoring Freedom and Resilience: Happy Juneteenth! Today, we honor Juneteenth, a day that symbolizes freedom and resilience. At Mellicell Inc., we stand in solidarity with the African American community, celebrating their strength and contributions. As we work towards better health solutions, we’re reminded of the importance of equality in every aspect of life. Let’s continue to push for justice and inclusivity together. Happy Juneteenth! #Juneteenth #Equality #Inclusion #Mellicell

🇺🇸 To all who served, thank you! 🇺🇸 Your courage and dedication inspire us every day at MelliCell as we strive to improve health outcomes for all. We honor your sacrifices and commitment. #MemorialDay #HonorAndRemember #MelliCell #Diabetes #Obesity #Biotech #HealthcareInnovation #DiabetesResearch #ObesityTreatment #Veterans #NeverForget

🌟 Breaking Through in Biotech: Mellicell Inc. 🌟 📍 Meet the game-changers! Mellicell’s co-founders, Prince Nnah and Benjamin Pope, are on a mission to redefine healthcare. Their startup is setting sights on revolutionizing treatments for obesity and diabetes. 🔬 Science Meets Strategy: Harvard-educated Benjamin Pope brings pioneering stem cell advancements to the table, while Prince Nnah, seasoned in scaling startups to unicorn status, steers the strategic helm. 🤝 Unified by Vision: From personal battles with diabetes to a fateful meeting, their story isn't just inspiring—it's a blueprint for innovation. 🚀 On the Rise: As Mellicell gears up for its next major funding round, watch this space. We're not just building a company; we're igniting a movement in healthcare. 💡 Stay Tuned: #Innovation #Obesity #Diabetes #HealthcareRevolution #Mellicell

🔬🌱 Mellicell Inc. is honored to receive a $275,000 grant from the U.S. National Science Foundation for pioneering research on "Industrial Scale Technology for Drug Development in Mature Human Fat Cells." Learn more about this exciting milestone: https://lnkd.in/e5e-grSt We're on a mission to cure obesity and diabetes! #NSFGrant #Innovation #Diabetes #obesity

#SheMadeHistory : Celebrating Women's contribution across time Today we honor 🌟 Flossie Wong-Staal (1947 – 2020) Who Was Flossie Wong-Staal? Flossie Wong-Staal was a visionary molecular biologist and virologist. She was born in China, raised in Hong Kong and flourished in the US. What Did She Achieve? She unlocked the mystery of HIV! Her groundbreaking work in the early '80s led to the genetic mapping of HIV, paving the way for critical advancements in diagnosis, treatment, and understanding of the disease. Her contributions were instrumental in developing the first HIV blood test, marking a turning point in the global fight against the AIDS epidemic. Why Does She Matter? Her relentless pursuit of knowledge and solutions transformed HIV from a death sentence into a manageable condition for many. Flossie Wong-Staal’s legacy is not just in her scientific discoveries but in her role as a trailblazer for women in STEM, embodying resilience, intelligence, and compassion. Flossie Wong-Staal’s story reminds us of the impact one person can have on humanity's journey toward health and understanding. 🌺 #WomensHistoryMonth #WomeninSTEM #FlossieWongStaal #ScientificLegacy #Diabesity #InspirationInScience #Mellicell

Metric
Company Name	MelliCell	Modular Medical
Symbol
MSH ID	COM:MELLICELL	COM:MODULARMEDICAL
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical Devices
Country	US	US
Stage	Grant	Post-IPO Equity
Employee Count
Website	mellicell.com	modularmedical.com
LinkedIn	mellicell	modular-medical
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	674	1.18K
Web Traffic Growth	-0.19	1.72
Valuation
Raised Capital		8.20M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MELLICELL

MelliCell

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue